Coming into the Modern Era – CMS Creates Interagency Task Force to…
To control rising costs under Medicare, the Affordable Care Act, and Medicare Access and CHIP Reauthorization Act of 2015…
Monthly Publications
In Depth
Subscribe Now
In Depth
coverage of timely
Life Science
Compliance issues
Subscribe Now
Monthly Archives
April 2018
CMS Proposes Changes to Part D and Medicare Advantage
Earlier this year, CMS proposed changes to the Medicare Advantage and Part D programs through the Advanced Notice and Draft Call…
FDA Plans to Review Promotional Research
According to new releases from the FDA, it plans to look at several issues related to biopharma advertising and promotion. FDA is…
Conflicts of Interest: When Should We Pay Attention
We have previously written about financial conflicts of interest and whether physicians can disseminate impartial scientific…
The Day After Tomorrow – The Drug Pricing Transparency Chorus Grows Louder
Drug pricing transparency, as a concept at least, is here to stay. However, the details of what that means and the new obligations…
Senate Holds Hearing on 340B Drug Pricing Program
On Thursday, March 15, 2018, the United States Senate Committee on Health, Education, Labor & Pensions held a hearing…
Gottlieb Discusses Opioids and Lays Out Vision – Google it’s…
On Wednesday, April 4, 2018, Food and Drug Administration (FDA) Commissioner Scott Gottlieb spoke at the National Rx Drug Abuse…
House of Representatives Holds Two-Day Hearing on Opioids
Recently the Committee on Energy and Commerce Subcommittee on Health held a hearing entitled, “Combating the Opioid Crisis:…
Is There a Decrease in FDA Regulations?
According to an article in the Economist, FDA’s Commissioner Scott Gottlieb has overseen a fairly significant decrease in the…
Higher Outpatient Drug Spending At 340B Hospitals, According to New…
A new analysis finds that hospitals which participate in the 340B Drug Discount Program have higher per patient outpatient…